

# CITATION REPORT

List of articles citing

## Clinical pharmacokinetics of fluoxetine

DOI: 10.2165/00003088-199426030-00004  
Clinical Pharmacokinetics, 1994, 26, 201-14.

**Source:** <https://exaly.com/paper-pdf/25271926/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
221	Newer and Older Antidepressants. <i>CNS Drugs</i> , <b>1994</b> , 2, 479-497	6.7	16
220	Simultaneous quantification of fluoxetine, norfluoxetine, and desipramine using gas chromatography with nitrogen-phosphorus detection. <b>1995</b> , 34, 143-7		11
219	Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in older patients with depressive illness. <b>1995</b> , 6, 64-84		25
218	Fluoxetine. <i>CNS Drugs</i> , <b>1995</b> , 3, 305-322	6.7	7
217	Gender Differences in Psychiatry. <i>CNS Drugs</i> , <b>1995</b> , 3, 393-407	6.7	6
216	Laboratory diagnosis of poisonings. <b>1996</b> , 25-236		3
215	Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. <i>Clinical Pharmacokinetics</i> , <b>1996</b> , 31, 444-69	6.2	159
214	Pathophysiology and management of the serotonin syndrome. <b>1996</b> , 30, 527-33		95
213	Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk. <b>1996</b> , 36, 42-7		75
212	Pharmacokinetics of Mirtazapine from Orally Administered Tablets: Influence of Gender, Age and Treatment Regimen. <b>1996</b> , 11, 497-509		34
211	Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography-mass spectrometry. <b>1996</b> , 682, 265-72		67
210	The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. <b>1996</b> , 60, 512-21		116
209	Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients. <b>1996</b> , 686, 51-63		63
208	Inhibition of rat brain monoamine oxidase enzymes by fluoxetine and norfluoxetine. <b>1996</b> , 354, 17-24		18
207	Stereoselective Determination of Fluoxetine and Norfluoxetine Enantiomers in Plasma Samples by High-Performance Liquid Chromatography. <b>1996</b> , 19, 1927-1935		24
206	CONTENTS. <b>1997</b> , 14,		
205	Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). <b>1997</b> , 17 Suppl 18, 21-7		46

204	Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users. <i>Clinical Pharmacokinetics</i> , <b>1997</b> , 33, 344-400	6.2	63
203	Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. <i>Clinical Pharmacokinetics</i> , <b>1997</b> , 33, 454-71	6.2	129
202	Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. <i>Clinical Pharmacokinetics</i> , <b>1997</b> , 32 Suppl 1, 1-21	6.2	262
201	Determination of p-trifluoromethylphenol, a metabolite of fluoxetine, in tissues and body fluids using an electron-capture gas chromatographic procedure. <b>1997</b> , 698, 103-9		15
200	Quantification of fluoxetine and norfluoxetine serum levels by reversed-phase high-performance liquid chromatography with ultraviolet detection. <b>1997</b> , 704, 259-63		23
199	Fluoxetine-induced movement disorders and deficient CYP2D6 enzyme activity. <b>1997</b> , 12, 624-5		19
198	Clinical implications of appetite suppressants. <b>1998</b> , 17, 273-286		
197	Determination of fluoxetine and its metabolite norfluoxetine in serum and brain areas using high-performance liquid chromatography with ultraviolet detection. <b>1998</b> , 707, 175-80		44
196	Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. <i>Clinical Pharmacokinetics</i> , <b>1998</b> , 34, 281-302	6.2	120
195	The metabolism of zolmitriptan: effects of an inducer and an inhibitor of cytochrome p450 on its pharmacokinetics in healthy volunteers. <b>1998</b> , 15, 515-22		12
194	Effect of fluoxetine on pharmacokinetics of ritonavir. <b>1998</b> , 42, 3107-12		35
193	Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. <b>1999</b> , 96, 13512-7		329
192	Fluoxetine bioequivalence study: quantification of fluoxetine and norfluoxetine by liquid chromatography coupled to mass spectrometry. <b>1999</b> , 39, 1053-61		19
191	Simultaneous determination of citalopram, fluoxetine, paroxetine and their metabolites in plasma and whole blood by high-performance liquid chromatography with ultraviolet and fluorescence detection. <b>1999</b> , 734, 229-46		102
190	Distribution and excretion of fluoxetine and norfluoxetine in human milk. <b>1999</b> , 48, 521-7		110
189	Block by fluoxetine of volume-regulated anion channels. <b>1999</b> , 126, 508-14		50
188	Inhibition of neuronal KV potassium currents by the antidepressant drug, fluoxetine. <b>1999</b> , 128, 1609-15		49
187	Cerebral functional magnetic resonance imaging activation modulated by a single dose of the monoamine neurotransmission enhancers fluoxetine and fenozolone during hand sensorimotor tasks. <b>1999</b> , 19, 1365-75		63

186	Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors. <b>1999</b> , 19, 443-66		107
185	Inhibition by fluoxetine of voltage-activated ion channels in rat PC12 cells. <b>1999</b> , 367, 113-8		34
184	Effects of serotonin re-uptake inhibition on ventilatory control in goats. <b>1999</b> , 115, 1-10		14
183	Effects of liver disease on pharmacokinetics. An update. <i>Clinical Pharmacokinetics</i> , <b>1999</b> , 37, 399-431	6.2	168
182	Conventional and new antidepressant drugs in the elderly. <b>2000</b> , 61, 353-96		99
181	Fluoxetine. <i>CNS Drugs</i> , <b>2000</b> , 14, 51-80	6.7	27
180	Effects of obesity on pharmacokinetics implications for drug therapy. <i>Clinical Pharmacokinetics</i> , <b>2000</b> , 39, 215-31	6.2	437
179	Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness. <b>2001</b> , 61, 81-110		65
178	Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. <i>Journal of Clinical Psychopharmacology</i> , <b>2001</b> , 21, 161-6	1.7	48
177	Serum concentrations of fluoxetine in the clinical treatment setting. <i>Therapeutic Drug Monitoring</i> , <b>2001</b> , 23, 139-47	3.2	48
176	Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. <i>Journal of Clinical Psychopharmacology</i> , <b>2001</b> , 21, 330-4	1.7	48
175	Inhibition of intestinal absorption of 5-methyltetrahydrofolate by fluoxetine. <b>2001</b> , 57, 71-79		
174	Modeling panic attacks. <b>2001</b> , 25, 647-59		173
173	Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. <b>2001</b> , 52, 96-9		33
172	Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. <b>2001</b> , 50, 718-29		309
171	O-Dealkylation of fluoxetine in relation to CYP2C19 gene dose and involvement of CYP3A4 in human liver microsomes. <b>2002</b> , 300, 105-11		16
170	Fluoxetine pharmacokinetics in pediatric patients. <i>Journal of Clinical Psychopharmacology</i> , <b>2002</b> , 22, 568-75		53
169	Plasma concentrations of the enantiomers of fluoxetine and norfluoxetine: sources of variability and preliminary observations on relations with clinical response. <i>Therapeutic Drug Monitoring</i> , <b>2002</b> , 24, 616-27	3.2	35

168	Benefits and risks to mother and infant of drug treatment for postnatal depression. <b>2002</b> , 25, 903-11	36
167	Inhibition of K <sup>+</sup> currents of outer hair cells in guinea pig cochlea by fluoxetine. <b>2002</b> , 453, 159-66	8
166	Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. <b>2002</b> , 90, 144-9	25
165	Simultaneous determination of fluoxetine and its metabolite p-trifluoromethylphenol in human liver microsomes using a gas chromatographic-electron-capture detection procedure. <b>2002</b> , 769, 305-11	18
164	Liquid chromatography/tandem mass spectrometry for the determination of fluoxetine and its main active metabolite norfluoxetine in human plasma with deuterated fluoxetine as internal standard. <b>2002</b> , 16, 1844-50	29
163	Modulation of 5-HT <sub>4</sub> receptor function in the rat isolated ileum by fluoxetine: the involvement of endogenous 5-hydroxytryptamine. <b>2002</b> , 136, 150-6	5
162	Transplacental transfer of citalopram, fluoxetine and their primary demethylated metabolites in isolated perfused human placenta. <b>2002</b> , 109, 1003-8	54
161	Up-regulation of 5-HT <sub>2B</sub> receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration. <b>2002</b> , 27, 113-20	102
160	When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. <b>2003</b> , 38, 843-53	351
159	Differential acute effects of fluoxetine on frontal and auditory cortex networks in vitro. <b>2003</b> , 973, 151-60	38
158	Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients. <b>2003</b> , 783, 25-31	47
157	Direct stereoselective assay of fluoxetine and norfluoxetine enantiomers in human plasma or serum by two-dimensional gas-liquid chromatography with nitrogen-phosphorus selective detection. <b>2003</b> , 783, 481-90	18
156	Drug Interaction of Fluvoxamine and Fluoxetine with Nevirapine in HIV-1-Infected Individuals. <b>2003</b> , 23, 629-37	12
155	Bioequivalence Behind the Scenes. <b>2003</b> , 1, 179-189	2
154	Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. <b>2003</b> , 101, 3212-9	131
153	Fluoxetine inhibits A-type potassium currents in primary cultured rat hippocampal neurons. <b>2004</b> , 1018, 201-7	31
152	Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. <b>2004</b> , 59, 869-73	57
151	NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of fluoxetine. <b>2004</b> , 71, 193-280	21

150	A rapid HPLC-DAD method for the analysis of fluoxetine and norfluoxetine in plasma from overdose patients. <b>2004</b> , 36, 351-6		40
149	Rapid quantitation of fluoxetine and norfluoxetine in serum by micro-disc solid-phase extraction with high-performance liquid chromatography-ultraviolet absorbance detection. <b>2004</b> , 804, 319-26		33
148	Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations. <i>Clinical Pharmacokinetics</i> , <b>2004</b> , 43, 361-94	6.2	60
147	Update on psychotropic medication use in renal disease. <b>2004</b> , 45, 34-48		44
146	Fluoxetine facilitates use-dependent excitability of human primary motor cortex. <b>2004</b> , 115, 2157-63		26
145	Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers. <b>2004</b> , 44, 1252-9		21
144	Subtherapeutic risperidone serum concentrations in an adolescent during hemodialysis: a pharmacological puzzle. <i>Therapeutic Drug Monitoring</i> , <b>2005</b> , 27, 558-61	3.2	5
143	Feasibility of transdermal delivery of fluoxetine. <b>2005</b> , 6, E144-9		29
142	Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement. <b>2005</b> , 27, 29-42		116
141	Effects of the selective serotonin reuptake inhibitor, fluoxetine, on regional gastric contractility. <b>2005</b> , 17, 76-82		22
140	Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine. <b>2005</b> , 144, 821-9		140
139	Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. <b>2005</b> , 97, 296-301		84
138	Bioequivalence evaluation of two brands of fluoxetine 20 mg capsules (Flutin and Prozac) in healthy human volunteers. <b>2005</b> , 26, 243-7		1
137	Inhibitory effects of psychotropic drugs on mexiletine metabolism in human liver microsomes: prediction of in vivo drug interactions. <b>2005</b> , 35, 549-60		17
136	An overview of psychotropic drug-drug interactions. <b>2005</b> , 46, 464-94		98
135	Use of psychotropic medications in treating mood disorders during lactation : practical recommendations. <i>CNS Drugs</i> , <b>2006</b> , 20, 187-98	6.7	70
134	Excretion and ecotoxicity of pharmaceutical and personal care products in the environment. <b>2006</b> , 63, 113-30		319
133	Involvement of enzymes other than CYPs in the oxidative metabolism of xenobiotics. <b>2006</b> , 2, 895-921		73

132	Emerging Histiotypic Properties of Cultured Neuronal Networks. <b>2006</b> , 193-214		1
131	Lack of pharmacokinetic interaction when switching from fluoxetine to milnacipran. <b>2006</b> , 21, 153-8		9
130	Rapid and direct measurement of free concentrations of highly protein-bound fluoxetine and its metabolite norfluoxetine in plasma. <b>2006</b> , 20, 39-47		31
129	Comparison of liquid chromatography with fluorescence detection to liquid chromatography-mass spectrometry for the determination of fluoxetine and norfluoxetine in human plasma. <b>2006</b> , 830, 372-6		37
128	Bioequivalence testing of a new tablet formulation of generic fluoxetine. <b>2006</b> , 31, 35-40		2
127	Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. <b>2006</b> , 186, 362-72		184
126	Pharmacokinetic interaction between fluoxetine and metoclopramide in healthy volunteers. <b>2006</b> , 27, 285-9		15
125	Serotonin function is associated with behavioral response to a novel conspecific in marmosets. <b>2006</b> , 68, 812-24		13
124	T-type calcium channels are inhibited by fluoxetine and its metabolite norfluoxetine. <b>2006</b> , 69, 1963-8		56
123	Efficacy of noradrenergic and serotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial. <i>Journal of Clinical Psychopharmacology</i> , <b>2007</b> , 27, 135-42	1.7	40
122	Enantiospecific sublethal effects of the antidepressant fluoxetine to a model aquatic vertebrate and invertebrate. <b>2007</b> , 69, 9-16		189
121	Antidepressants induce cellular insulin resistance by activation of IRS-1 kinases. <b>2007</b> , 36, 305-12		40
120	Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain. <b>2007</b> , 32, 2152-62		230
119	Immunoaffinity in-tube solid phase microextraction coupled with liquid chromatography-mass spectrometry for analysis of fluoxetine in serum samples. <b>2007</b> , 1174, 72-7		78
118	Chiral selectors for enantioresolution and quantitation of the antidepressant drug fluoxetine in pharmaceutical formulations by (19)F NMR spectroscopic method. <b>2007</b> , 601, 130-8		26
117	Determination of fluoxetine, norfluoxetine and their enantiomers in rat plasma and brain samples by liquid chromatography with fluorescence detection. <b>2007</b> , 852, 519-28		46
116	Amine oxidases and monooxygenases in the in vivo metabolism of xenobiotic amines in humans: has the involvement of amine oxidases been neglected?. <b>2007</b> , 21, 467-80		31
115	Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat. <b>2008</b> , 97, 1593-605		25

114	Cytochromes P450: A Structure-Based Summary of Biotransformations Using Representative Substrates. <b>2008</b> , 40, 1-100		98
113	Olanzapine/fluoxetine: a review of its use in the treatment of acute bipolar depression. <b>2008</b> , 68, 1115-37		17
112	Estimation of embryotoxic effect of fluoxetine using embryonic stem cell differentiation system. <b>2008</b> , 83, 871-7		24
111	Pharmacokinetics and pharmacodynamics of norfluoxetine in rats: Increasing extracellular serotonin level in the frontal cortex. <b>2009</b> , 92, 469-73		30
110	The role of ceramide in major depressive disorder. <b>2009</b> , 259 Suppl 2, S199-204		38
109	Physiological modes of action of fluoxetine and its human metabolites in algae. <b>2009</b> , 43, 6830-7		51
108	Fluoxetine treatment affects nitrogen waste excretion and osmoregulation in a marine teleost fish. <b>2009</b> , 93, 253-60		9
107	Fluoxetine treatment affects nitrogen waste excretion and osmoregulation in a marine teleost fish. <b>2009</b> , 95, 164-71		37
106	Determination of Fluoxetine and Norfluoxetine in Human Serum and Urine by HPLC Using a Cholesterol Column with Fluorescence Detection. <b>2009</b> , 32, 1141-1151		12
105	Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 42-56	3.2	102
104	Comparative bioavailability and tolerability of a single 20-mg dose of two fluoxetine hydrochloride dispersible tablet formulations in fasting, healthy Chinese male volunteers: an open-label, randomized-sequence, two-period crossover study. <b>2010</b> , 32, 1977-86		4
103	Selective deficits in erythrocyte docosahexaenoic acid composition in adult patients with bipolar disorder and major depressive disorder. <b>2010</b> , 126, 303-11		115
102	Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression. <b>2010</b> , 10, 651-70		15
101	DETERMINATION OF FLUOXETINE ENANTIOMERS IN HUMAN SERUM AND URINE BY ISOCRATIC HPLC AND PRE-COLUMN FLUORESCENCE DERIVATIZATION WITH (R)-(+)-4-NITRO-7-(2-CHLOROFORMYLPYRROLIDIN-1-YL)-2,1,3-BENZOXADIAZOLE. <b>2010</b> , 33, 481-490		6
100	Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study. <b>2010</b> , 71, 360-8		7
99	Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder. <i>CNS Drugs</i> , <b>2010</b> , 24, 245-62	6.7	20
98	SIMPLE DETERMINATION OF FLUOXETINE AND NORFLUOXETINE IN HUMAN SERUM AND URINE BY DASYLATION FOLLOWED BY HPLC WITH VISIBLE LIGHT DETECTION. <b>2010</b> , 33, 1405-1415		1
97	Effect of fluoxetine on the pharmacokinetics of lansoprazole: a two-treatment period study in healthy male subjects. <b>2011</b> , 31, 727-33		6



96	Predictive validity of a non-induced mouse model of compulsive-like behavior. <b>2011</b> , 221, 55-62	57
95	Photooxidation of the antidepressant drug Fluoxetine (Prozac <sup>®</sup> ) in aqueous media by hybrid catalytic/ozonation processes. <b>2011</b> , 45, 2782-94	52
94	Prediction of infant drug exposure through breastfeeding: population PK modeling and simulation of fluoxetine exposure. <b>2011</b> , 89, 830-6	21
93	Fluoxetine affects antioxidant system and promotes apoptotic signaling in Wistar rat liver. <b>2011</b> , 659, 61-6	52
92	Pharmacokinetics of fluoxetine in rhesus macaques following multiple routes of administration. <b>2011</b> , 88, 44-9	24
91	A validated microfluidics-based LC-chip-MS/MS method for the quantitation of fluoxetine and norfluoxetine in rat serum. <b>2012</b> , 33, 3370-9	23
90	Drugs against Acute and Chronic Pain. <b>2012</b> , 403-428	2
89	Effects of fluoxetine on cloned Kv4.3 potassium channels. <b>2013</b> , 1500, 10-8	7
88	Comparing the effects of fluoxetine and imipramine on total cholesterol, triglyceride, and weight in patients with major depression. <b>2013</b> , 21, 4	13
87	Selective serotonin reuptake inhibitors (SSRIs) inhibit insulin secretion and action in pancreatic $\beta$ cells. <b>2013</b> , 288, 5682-93	50
86	Quantitative cross-species extrapolation between humans and fish: the case of the anti-depressant fluoxetine. <b>2014</b> , 9, e110467	99
85	PBPK model describes the effects of comedication and genetic polymorphism on systemic exposure of drugs that undergo multiple clearance pathways. <b>2014</b> , 95, 550-7	45
84	Pharmacokinetics of antidepressants in patients with hepatic impairment. <i>Clinical Pharmacokinetics</i> , <b>2014</b> , 53, 1069-81	6.2 5
83	Fluoxetine potentiation of omega-3 fatty acid antidepressant effect: evaluating pharmacokinetic and brain fatty acid-related aspects in rodents. <b>2014</b> , 103, 3316-25	15
82	Population PK modelling and simulation based on fluoxetine and norfluoxetine concentrations in milk: a milk concentration-based prediction model. <b>2014</b> , 78, 918-28	12
81	Characterizing the effect of cytochrome P450 (CYP) 2C8, CYP2C9, and CYP2D6 genetic polymorphisms on stereoselective N-demethylation of fluoxetine. <b>2014</b> , 26, 166-73	17
80	Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4. <b>2014</b> , 95, 653-62	56
79	Pharmacogenetics of chronic pain management. <b>2014</b> , 47, 1169-87	72

78	Trends in antidepressant prescriptions for children and adolescents in Germany from 2005 to 2012. <b>2014</b> , 23, 1268-72	18
77	Fluoxetine Decreases the Proliferation and Adipogenic Differentiation of Human Adipose-Derived Stem Cells. <i>International Journal of Molecular Sciences</i> , <b>2015</b> , 16, 16655-68	6.3 16
76	Selective serotonin reuptake inhibitors facilitate ANO6 (TMEM16F) current activation and phosphatidylserine exposure. <b>2015</b> , 467, 2243-56	10
75	The antidepressant fluoxetine protects the hippocampus from brain damage in experimental pneumococcal meningitis. <b>2015</b> , 297, 89-94	14
74	Development of drug-in-adhesive patch formulations for transdermal delivery of fluoxetine: In vitro and in vivo evaluations. <b>2015</b> , 487, 49-55	32
73	Differential induction of FosB isoforms throughout the brain by fluoxetine and chronic stress. <b>2015</b> , 99, 28-37	49
72	Sub-chronic exposure to fluoxetine in juvenile oysters ( <i>Crassostrea gigas</i> ): uptake and biological effects. <b>2016</b> , 23, 5002-18	15
71	A guide to medication adherence in depression. <b>2016</b> , 5, 259-261	
70	Simultaneous quantitation of acetylsalicylic acid and clopidogrel along with their metabolites in human plasma using liquid chromatography tandem mass spectrometry. <b>2016</b> , 30, 466-73	14
69	Treatment with the selective serotonin reuptake inhibitor, fluoxetine, attenuates the fish hypoxia response. <b>2016</b> , 6, 31148	14
68	Drug treatment of autism spectrum disorder and its comorbidities in children and adolescents. <b>2016</b> , 22, 151-161	14
67	Antidepressants. <b>2016</b> , 205-245	
66	QbD-Driven Development and Validation of a Bioanalytical LC-MS Method for Quantification of Fluoxetine in Human Plasma. <b>2016</b> , 54, 736-43	23
65	Separation and determination of selected psychotropic drugs in human serum by SPE/HPLC/DAD on C18 and Polar-RP columns. <b>2017</b> , 40, 75-82	4
64	DFT, NBO and molecular docking studies of the adsorption of fluoxetine into and on the surface of simple and sulfur-doped carbon nanotubes. <b>2017</b> , 420, 267-275	13
63	The SSRI fluoxetine exhibits mild effects on the reproductive axis in the cichlid fish <i>Cichlasoma dimerus</i> (Teleostei, Cichliformes). <b>2017</b> , 171, 370-378	15
62	Improved Analytical Approach Based on QuEChERS/UHPLC-PDA for Quantification of Fluoxetine, Clomipramine and their Active Metabolites in Human Urine Samples. <b>2017</b> , 41, 45-53	15
61	Ion Channel and Neurotransmitter Modulators as Electroceutical Approaches to the Control of Cancer. <b>2017</b> , 23, 4827-4841	22

60	Neonatal treatment with fluoxetine improves mitochondrial respiration and reduces oxidative stress in liver of adult rats. <b>2018</b> , 119, 6555-6565	10
59	Does fluoxetine exposure affect hypoxia tolerance in the Gulf toadfish, <i>Opsanus beta</i> ?. <b>2018</b> , 199, 55-64	7
58	Simultaneous determination of fluoxetine and norfluoxetine in dried blood spots using high-performance liquid chromatography-tandem mass spectrometry. <b>2018</b> , 52, 85-93	12
57	Detection and Occurrence of PPCPs in the Environment. <b>2018</b> , 119-176	
56	Fluoxetine can inhibit coxsackievirus-B4 E2 in vitro and in vivo. <b>2018</b> , 159, 130-133	14
55	Late presentation of Torsades de Pointes related to fluoxetine following a multiple drug overdose. <b>2018</b> , 6, 59	1
54	Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. <b>2018</b> , 19, 1057-1070	53
53	Evaluating the efficacy and safety of antidepressants in patients with bipolar disorder. <b>2019</b> , 18, 893-913	5
52	A protocol for a randomised controlled, double-blind feasibility trial investigating fluoxetine treatment in improving memory and learning impairments in patients with mesial temporal lobe epilepsy: Fluoxetine, Learning and Memory in Epilepsy (FLAME trial). <b>2019</b> , 5, 87	1
51	Potential Adverse Cardiovascular Effects of Treatment With Fluoxetine and Other Selective Serotonin Reuptake Inhibitors (SSRIs) in Patients With Geriatric Depression: Implications for Atherogenesis and Cerebrovascular Dysregulation. <b>2019</b> , 10, 898	10
50	Pharmacokinetic considerations for current state-of-the-art antidepressants. <b>2019</b> , 15, 831-847	11
49	An experimental test of the ovulatory homolog model of female orgasm. <b>2019</b> , 116, 20267-20273	6
48	Sleep modulating agents. <b>2019</b> , 29, 2025-2033	2
47	Increasing serotonin bioavailability in preweaned dairy calves impacts hematology, growth, and behavior. <b>2019</b> , 69, 42-50	8
46	Selective Serotonin Reuptake Inhibitors. <b>2019</b> , 103-128	5
45	Pharmacokinetics and Transplacental Transfer of Fluoxetine Enantiomers and Their Metabolites in Pregnant Women. <b>2019</b> , 105, 1003-1008	1
44	An Interesting Case of Carbamazepine-Induced Stevens-Johnson Syndrome. <b>2018</b> , 6, 1	5
43	Comparison of predicted intrinsic hepatic clearance of 30 pharmaceuticals in canine and feline liver microsomes. <b>2019</b> , 49, 177-186	2

42	Fluoxetine exposure disrupts food intake and energy storage in the cichlid fish <i>Cichlasoma dimerus</i> (Teleostei, Cichliformes). <b>2020</b> , 238, 124609	16
41	Enantioselective LC analysis and determination of selective serotonin reuptake inhibitors. <b>2020</b> , 34, e4730	6
40	In vitro characterization and in vitro to in vivo predictions of drug-drug interactions. <b>2020</b> , 273-309	
39	Investigating the potential of fish oil as a nutraceutical in an animal model of early life stress. <b>2020</b> , 1-23	9
38	Inhibitory effects of antidepressant fluoxetine on cloned Kv2.1 potassium channel expressed in HEK293 cells. <b>2020</b> , 878, 173097	3
37	Fluoxetine in acute treatment of children and adolescents with obsessive-compulsive disorder: a systematic review and meta-analysis. <b>2020</b> , 74, 461-469	1
36	Peripheral serotonin regulates glucose and insulin metabolism in Holstein dairy calves. <b>2021</b> , 74, 106519	1
35	Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. <b>2021</b> , 22, 561-628	3
34	Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics. <b>2021</b> , 22, 485-503	4
33	Prediction of Fluoxetine and Norfluoxetine Pharmacokinetic Profiles Using Physiologically Based Pharmacokinetic Modeling. <b>2021</b> , 61, 1505-1513	
32	Systems Toxicology Approach for Assessing Developmental Neurotoxicity in Larval Zebrafish. <b>2021</b> , 12, 652632	2
31	An update on the treatment of premature ejaculation: A systematic review. <b>2021</b> , 19, 281-302	1
30	Employ FTIR spectroscopic method for determination of certain multiple sclerosis medications in plasma and pharmaceutical formulations. <b>2021</b> , 167, 106329	1
29	Improved Synthesis of Bioactive Molecules Through Flow Chemistry. <b>2021</b> , 1	0
28	Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. <b>1999</b> , 96, 13512-13517	1
27	Pharmaceuticals and Personal-Care Products. 207-227	3
26	Therapeutic drug monitoring of antidepressants and psychoactive drugs. <b>2020</b> , 199-227	1
25	Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. <i>Journal of Clinical Psychopharmacology</i> , <b>1996</b> , 16, 273-85	1.7 61

24	Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. Part II. <i>Journal of Clinical Psychopharmacology</i> , <b>1996</b> , 16, 345-55	1.7	59
23	Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. <i>Journal of Clinical Psychopharmacology</i> , <b>1997</b> , 17, 15-21	1.7	34
22	Decrease of valproic acid concentration in the blood when coprescribed with fluoxetine. <i>Journal of Clinical Psychopharmacology</i> , <b>1997</b> , 17, 139-40	1.7	3
21	Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology. <i>Journal of Clinical Psychopharmacology</i> , <b>2002</b> , 22, 440-1	1.7	33
20	Issues in methodology and applications for therapeutic drug monitoring of fluoxetine and norfluoxetine enantiomers. <i>Therapeutic Drug Monitoring</i> , <b>1998</b> , 20, 20-4	3.2	7
19	Therapeutic monitoring of psychoactive drugs - antidepressants: a review. <i>Biomedical Papers of the Medical Faculty of the University Palacky&amp;#x0301;, Olomouc, Czechoslovakia</i> , <b>2015</b> , 159, 35-43	1.7	10
18	Vinpocetine attenuates fluoxetine-induced liver damage in rats; Role of Nrf2 and PPAR- $\alpha$ <i>Human and Experimental Toxicology</i> , <b>2021</b> , 40, S509-S518	3.4	1
17	Fluoxetine does not Impair Motor Function in Patients with Parkinson's Disease: Correlation Between Mood and Motor Functions with Plasma Concentrations of Fluoxetine/ Norfluoxetine. <i>Journal of Neurology &amp; Stroke</i> , <b>2017</b> , 6,	0.7	
16	Randomized Controlled Trials and the Efficacy of Psychotropic Medications. <b>2020</b> , 1-56		
15	Pharmacokinetics of fluoxetine in horses following oral administration. <i>Journal of Veterinary Pharmacology and Therapeutics</i> , <b>2021</b> ,	1.4	0
14	Pharmacokinetics of fluoxetine in pregnant baboons ( <i>Papio</i> spp.). <i>Journal of the American Association for Laboratory Animal Science</i> , <b>2014</b> , 53, 708-16	1.3	2
13	Weekly Supervised Administration of Oral Antipsychotics: An Alternative to Long-Acting Injections?. <i>CNS Drugs</i> , <b>2022</b> , 36, 315	6.7	1
12	Elucidating the Interactions of Fluoxetine with Human Transferrin Employing Spectroscopic, Calorimetric, and Approaches: Implications of a Potent Alzheimer's Drug.. <i>ACS Omega</i> , <b>2022</b> , 7, 9015-9023	3.9	3
11	Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19.. <i>International Journal of Molecular Sciences</i> , <b>2022</b> , 23,	6.3	0
10	The effects of antidepressants fluoxetine, sertraline, and amitriptyline on the development of antibiotic resistance in <i>Acinetobacter baumannii</i> .. <i>Archives of Microbiology</i> , <b>2022</b> , 204, 230	3	1
9	Untangling Absorption Mechanisms and Variability in Bioequivalence Studies Using Population Analysis.. <i>Pharmaceutical Research</i> , <b>2021</b> , 38, 2047	4.5	
8	Mechanisms underlying the hepatoprotective effect of silymarin on fluoxetine-induced liver injury in rats: the implication of peroxisome proliferator-activated receptor-gamma (PPAR- $\gamma$ ) <i>Comparative Clinical Pathology</i> ,	0.9	
7	The prescriber's guide to classic MAO-inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression. <i>CNS Spectrums</i> , 1-49	1.8	1

- 6 The Importance of Drug Dose Adjustment in Elderly Patients with Special Considerations for Patients on Diverse Co-medications and Antidepressants. **2022**, 231-272 ○
- 5 Impact of Pharmaceutical Compounds on the Microbial Ecology of Surface Water Resources. **2022**, 323-343 ○
- 4 Randomized Controlled Trials and the Efficacy of Psychotropic Medications. **2022**, 305-359 ○
- 3 In silico analysis of the antidepressant fluoxetine and similar drugs as inhibitors of the human protein acid sphingomyelinase: a related SARS-CoV-2 inhibition pathway. 1-14 2
- 2 Analysis of Adherence to Fluoxetine Treatment through its Plasma Concentration. 58, ○
- 1 Cost-effective pharmaceutical implants in fish: validating the performance of slow-release implants for the antidepressant fluoxetine. ○